Kristin Attiogbe
Family · Chevy Chase, MDNPI 1699055749
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (40.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Celltrion USA Inc. at 44.0% of the total. Among family clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 465 payments — averaging $91.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Celltrion USA Inc.$19K
- Johnson & Johnson$5K
- Pfizer$4K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Genentech USA, Inc.$3K
- AbbVie$2K
- plus $6K from 24 others
What the payments were for
- Consulting fees$11,32127%
- Speaking & faculty fees$1,5424%
- Travel & lodging$16,93440%
- Food & beverage$12,21529%
- Education$3561%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Celltrion USA Inc. | 39 | $18,630 |
| Johnson & Johnson | 46 | $5,410 |
| Pfizer | 45 | $3,932 |
| Takeda Pharmaceuticals U.S.A., Inc. | 47 | $3,234 |
| Genentech USA, Inc. | 6 | $2,937 |
| AbbVie | 74 | $2,196 |
| Bristol Myers Squibb | 29 | $1,053 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 64 | $876 |
| Janssen Scientific Affairs, LLC | 10 | $752 |
| Merck | 7 | $593 |
| Lilly USA, LLC | 14 | $427 |
| Ardelyx, Inc. | 11 | $415 |
| Sanofi | 12 | $367 |
| QOL Medical, LLC | 11 | $253 |
| Phathom Pharmaceuticals, Inc. | 12 | $225 |
| Therapeuticsmd, Inc. | 1 | $123 |
| Madrigal Pharmaceuticals | 4 | $121 |
| Intercept Pharmaceuticals, Inc. | 5 | $121 |
| Regeneron Healthcare Solutions, Inc. | 6 | $114 |
| Ipsen Biopharmaceuticals, Inc | 4 | $99 |
| E.r. Squibb & Sons, L.L.C. | 1 | $94 |
| Amgen | 3 | $67 |
| Braintree Laboratories, Inc. | 3 | $65 |
| Ironwood Pharmaceuticals, Inc | 3 | $57 |
| Daiichi Sankyo Inc. | 2 | $51 |
| Novo Nordisk | 2 | $45 |
| Aimmune Therapeutics, Inc. | 1 | $41 |
| Boston Scientific | 1 | $28 |
| Sandoz | 1 | $21 |
| Fresenius Kabi USA, LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$42,367 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 13 | $354,619 |
| LinzessLinaclotide | 12 | $19,393 |
| Dexlansoprazole DrDexlansoprazole | 23 | $6,572 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 35 | $5,536 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 84 | $4,857 |
| Mesalamine | 16 | $4,854 |
| Pantoprazole Sodium | 50 | $944 |
| Famotidine | 32 | $733 |
| Omeprazole | 46 | $553 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $5,410 | $354,61913 claims |
| AbbVieLinzess | $2,196 | $19,39312 claims |
| Braintree Laboratories, Inc.Sutab | $65 | $5,53635 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.
Other family in Chevy Chase
- Erika HoffmanPotomac$226K
- Caroline MansySalisbury$106K
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Ariana ChaoLutherville$85K
- Meredith SagalHunt Valley$82K
- Sharon Dudley-BrownBel Air$67K
- Joy MaulikSalisbury$47K
- Sametta SanyaoluFulton$37K
- Lisa ScottiBaltimore$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.